news paper icon

Analyzed News

REFILE-Lilly eyes more cancer deals, but wary of CAR-T, gene therapy

Eli Lilly and Co remains in the hunt for cancer drugs even after announcing an $8 billion purchase of Loxo Oncology this week, but it plans to remain on the sidelines when it comes to two of the hottest areas of drug development. [Source]

Publication Date:


Category: companyNews

Topics: cancer, lilly, refile-lilly, remains, the hunt

Source Link:

Related Articles